Isovorin

Levoleucovorin, the active ingredient in Isovorin, is a folate analog presented as a sterile solution for intramuscular and intravenous use. It is employed to mitigate toxicity from high‑dose methotrexate and to enhance the efficacy of fluoropyrimidine chemotherapy in cancer patients. It is commonly used in combination protocols for solid tumours and hematologic malignancies.

GNH USA supplies Isovorin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for clinical use.

Isovorin (levoleucovorin) is used to modulate folate pathways in oncology and chemotherapy rescue protocols. - High‑dose methotrexate therapy: reduces methotrexate‑induced toxicity and supports normal cell recovery. - 5‑Fluorouracil‑based chemotherapy: enhances antitumor activity by stabilising drug‑target interaction. - Pemetrexed treatment: lessens hematologic toxicity associated with antifolate agents.

Levoleucovorin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Transient rash: mild skin erythema or itching. - Elevated liver enzymes: temporary increase in hepatic transaminases. - Fatigue: mild, short‑lasting tiredness.

Serious or Rare Side Effects: - Severe hypersensitivity: anaphylactic reactions requiring immediate medical attention. - Renal failure: acute kidney injury in susceptible patients. - Hepatic dysfunction: significant liver injury or jaundice. - Hematologic abnormalities: neutropenia or thrombocytopenia. - Cardiovascular events: rare cases of arrhythmia or hypotension.

Before initiating therapy, clinicians should evaluate patient-specific risk factors. - Renal function: assess creatinine clearance and adjust dosing if impaired. - Hepatic function: monitor liver enzymes during treatment. - Concurrent methotrexate: ensure appropriate rescue timing to avoid excess toxicity. - Pregnancy: use only when benefits outweigh potential risks. - Allergy: discontinue immediately if hypersensitivity signs appear. - Store at ambient temperature: keep in original container, protect from light and moisture.

Levoleucovorin may interact with several agents; monitoring is essential.

Major Interactions (Avoid): - Methotrexate: inadequate rescue can increase toxicity. - Antifolates (e.g., pemetrexed): may diminish the protective effect of levoleucovorin. - High‑dose vitamin C: could interfere with folate metabolism.

Moderate Interactions (Monitor Closely): - 5‑Fluorouracil: dose adjustments may be required when combined. - Nephrotoxic drugs (e.g., cisplatin): monitor renal parameters. - Hepatotoxic drugs (e.g., acetaminophen): watch liver function tests.